<DOC>
	<DOCNO>NCT01240421</DOCNO>
	<brief_summary>This expanded access program open-label , multi-center study , consist PreTreatment Phase Treatment Phase . Patients locally advance metastatic breast cancer fulfill eligibility criterion treat . The program continue country eribulin approve , reimburse launched country , termination program Sponsor .</brief_summary>
	<brief_title>An Open-Label , Multi-Center , Expanded Access Program With Eribulin Treatment Advanced Breast Cancer Refractory</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Key Patient 's oncologist must document experience prior eribulin clinical trial Recurrent , locally advanced metastatic breast cancer progress last anticancer therapy Prior treatment , ineligibility , commercial unavailability follow therapy : 1 . Anthracyclines , taxanes , capecitabine 2 . Ixabepilone , country agent market 3 . Trastuzumab , Her2 positive disease 4 . Hormonal therapy , hormone receptorpositive disease 5 . All commercially available therapy , e.g . gemcitabine vinorelbine , use treatment advance breast cancer ( see NCCN guideline ) ECOG performance status great equal 2 Adequate kidney function : serum creatinine less equal 2.0 mg/dL creatinine clearance great equal 40 mL/min Adequate bone marrow function : absolute neutrophil count great equal 1.5 x 10^9/L , hemoglobin great equal 10 g/dL ( corrected growth factor transfusion ) , platelet count great equal 100 x 10^9/L Adequate liver function : total bilirubin less equal 1.5 x upper limit normal ( ULN ) , alkaline phosphatase , alanine aminotransferase , aspartate aminotransferase less equal 3 x ULN ( less equal 5 x ULN case liver metastasis ) . If alkaline phosphatase great 3 x ULN ( absence liver metastasis ) great 5 x ULN ( presence liver metastasis ) AND patient also know bone metastasis , liver specific alkaline phosphatase must use assess liver function instead total alkaline phosphatase Willing able comply aspect treatment protocol Provision write informed consent Female , age least 18 year Patients childbearing potential must agree abstinent use highly effective method contraception Key Eligibility eribulin study open region Existing anticancer therapyrelated toxicity grade 2 , except alopecia grade 2 neuropathy acceptable History congestive heart failure New York Heart Association Classification great grade II , unstable angina , myocardial infarction within past 6 month serious cardiac arrhythmia Electrocardiogram QTc interval great equal 500 msec base upon Bazett 's formula ( QTcB ) The Investigator believe patient medically unfit receive eribulin unsuitable reason Pregnancy ( positive BhCG test ) breastfeeding Hypersensitivity eribulin excipients Brain subdural metastasis , unless local therapy complete use corticosteroid indication discontinue least 4 week start treatment protocol . Any sign ( eg , radiologic ) and/or symptom brain metastasis must stable least 4 week start treatment protocol History concomitant medical condition , opinion Investigator , would compromise patient 's ability safely complete treatment protocol Known human immunodeficiency virus positivity , neutropenia cause eribulin treatment may make patient particularly susceptible infection . Meningeal carcinomatosis Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen Receipt follow treatment within specified period start treatment : 1 ) Any investigational drug within 4 week ; 2 ) Chemotherapy , radiation , biological target therapy within 2 week ; 3 ) Hormonal therapy within 1 week .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Metastatic breast cancer treatment option</keyword>
</DOC>